证券代码：002219 证券简称：恒康医疗 恒康医疗集团股份有限公司 投资者关系活动记录表 编号：2016-04 | --- | --- | --- | |------------------|------------------------|--------------------------| | | | | | | □ | 特定对象调研 □分析师会议 | | 投资者关系活动 | √媒体采访 □业绩说明会 | | | 类别 | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ 其他 | | | 参与单位名称及人 | 《中国经营报》 张春楠 | | | 员姓名 | | | | 时间 | 2016 年 9 月 8 | 日 | | 地点 | 电话采访 | | | 上市公司接待人员 | 董事会秘书 曹维 | | 1 | --- | --- | |----------------------|---------------------------------------------------------------------------------------------------- ...

证券代码：002219 证券简称：恒康医疗 恒康医疗集团股份有限公司 投资者关系活动记录表 编号：2016-06 | --- | --- | --- | |------------------|---------------------------|--------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ 媒体采访 □业绩说明会 | | | 类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □其他 | | | 参与单位名称及人 | 东吴证券股份有限公司 洪阳 | | | 员姓名 | 智银投资 赵婷 | | | 时间 | 2016 年 9 月 20 | 日 | | 地点 | 公司会议室 | | | 上市公司接待人员 | 董事会秘书曹维 李丹 | | 1 | --- | --- | |----------------------|---------------------------------------------------------------------------------- ...

证券代码：002219 证券简称：恒康医疗 恒康医疗集团股份有限公司 投资者关系活动记录表 编号：2016-07 | --- | --- | --- | |------------------|-------------------------|-----------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □其他 | | | 参与单位名称及人 | | 安诚财产保险股份有限公司 卢敬之 | | | 西南证券 张肖星 | | | 员姓名 | | 久乘投资管理（上海）有限公司 余江 | | | | 深圳德威资本投资管理有限公司 赵征 | | 时间 | 2016 年 12 月 7 | 日 | | 地点 | 公司会议室 | | 1 | --- | --- | |----------------------|----------------------------------------------- ...

编号：2021-01 证券代码：002219 证券简称：*ST 恒康 恒康医疗集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |-----------------------|--------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------|------------| | | □特定对象调研 □分析师会议 | | | | | 投资者关系活动 | □媒体采访 √业绩说明会 | | | | | 类别 | □新闻发布会 | □路演活动 | | | | | □现场参观 | | | | | | □其他 | | | | | 参与单位名称 | | 通过"全景·路演天下"网络平台参与公司 | 2020 | 年度网上业 | | 及人员姓名 | 绩说明会的投资 ...

证券代码：002219 证券简称：*ST 恒康 编号：2022-01 恒康医疗集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|--------------------------------------------|----------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | 投资者关系活动 | □媒体采访 √业绩说明会 | | | 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | | | 参与单位名称 | | 通过"全景·路演天下"网络平台参与公司 2021 年度网上业 | | 及人员姓名 | 绩说明会的投资者 | | | 时间 2022 | 年 5 月 11 日 | 15:00-17:00 | | | 地点 "全景·路演天下"（ | http://rs.p5w.net ） | | | | | | 上市公司接待人员 姓名 | 先生、财务总监刘军先生、董事会 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥805,193,959.15, representing an increase of 8.18% compared to the same period last year[7] - The net profit attributable to shareholders for Q3 2022 was ¥15,462,621.60, a significant increase of 185.56% year-on-year[7] - Basic earnings per share for Q3 2022 were ¥0.0189, reflecting a growth of 456.60% compared to the previous year[7] - Total operating revenue for the current period reached ¥2,326,660,478.27, an increase from ¥2,224,300,970.63 in the previous period, representing a growth of approximately 4.6%[36] - Net profit for the current period was ¥121,283,831.87, a significant recovery from a net loss of ¥57,174,950.52 in the previous period[38] - Basic earnings per share for the current period improved to ¥0.0344, compared to a loss of ¥0.0317 per share in the previous period[38] - The company's total profit for the current period was ¥147,571,758.68, a recovery from a total loss of ¥36,220,327.39 in the previous period[38] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥5,502,832,413.37, a decrease of 17.75% from the end of the previous year[7] - As of September 30, 2022, total assets amounted to ¥5,502,832,413.37, a decrease from ¥6,690,205,812.98 at the beginning of the year, representing a decline of approximately 17.7%[29] - Current assets decreased to ¥1,767,932,569.64 from ¥3,023,848,238.36, indicating a reduction of about 41.5%[29] - Total liabilities decreased to ¥3,794,910,476.50 from ¥5,104,155,707.98, reflecting a decline of approximately 25.7%[31] - The company's short-term borrowings significantly decreased from ¥1,274,371,644.23 to ¥99,850,000.00, a reduction of about 92.2%[31] - The company's total equity increased to ¥1,707,921,936.87 from ¥1,586,050,105.00, showing an increase of approximately 7.6%[31] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥97,923,313.84, down 53.27% year-on-year[7] - Cash flow from operating activities generated a net amount of ¥97,923,313.84, down from ¥209,549,867.80 in the previous period[42] - Cash inflow from operating activities totaled ¥2,332,736,027.28, compared to ¥2,184,543,218.48 in the previous period, reflecting an increase of approximately 6.8%[42] - Cash outflow from operating activities was ¥2,234,812,713.44, up from ¥1,974,993,350.68 in the previous period, indicating an increase of about 13.1%[42] - The net cash flow from financing activities was -1,037,090,264.24, a significant decrease compared to -43,062,707.58 from the previous period[45] - The net increase in cash and cash equivalents was -1,399,542,385.38, contrasting with an increase of 29,689,974.08 previously[45] - The ending balance of cash and cash equivalents was 591,558,206.67, down from 1,991,100,592.05 at the beginning of the period[45] Shareholder Information - Total number of common shareholders at the end of the reporting period was 32,374[20] - The largest shareholder, Beijing New Mileage Health Industry Group Co., Ltd., holds 25.30% of shares, totaling approximately 825.93 million shares[20] Company Changes - The company changed its name from "Hengkang Medical Group Co., LTD" to "New Journey Health Technology Group Co., LTD" effective September 26, 2022[26] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 3.84%, an increase of 13.39% compared to the previous year[7] - The company received government subsidies totaling ¥6,655,762.71 during the quarter, contributing to its non-operating income[8] - Interest expenses increased by 58.29% to approximately $106.21 million compared to the same period last year[16] - Interest income surged by 1775.60% to approximately $8.28 million due to increased interest from restructured investments[16] - Investment income rose by 237.29% to approximately $11.57 million, attributed to debt forgiveness[16] - Credit impairment losses increased significantly by 2319.25% to approximately $38.91 million, reflecting recoveries from previous disposals[16] - Tax refunds received increased by 367.44% to approximately $2.73 million compared to the previous year[16] - Cash paid for operating activities rose by 31.40% to approximately $388.97 million, driven by restructuring costs[16] - Cash received from the disposal of subsidiaries amounted to approximately $42 million, marking a 100% increase[16] - Cash received from investment activities reached approximately $100 million, reflecting bank wealth management redemptions[16]

Business Model and Strategy - The company reported a significant shift from a single pharmaceutical manufacturing business to a dual-driven "big health" industry model, focusing on both medical services and pharmaceutical manufacturing [28]. - The company is focusing on expanding its services in response to the increasing healthcare demands driven by aging population and chronic diseases [44]. - The management highlighted the ongoing healthcare reforms as both an opportunity and a challenge for the company's future growth [44]. - The company focuses on a dual-driven strategy of medical services and pharmaceutical manufacturing, enhancing its competitive edge in the healthcare industry [52]. - The company aims to strengthen its regional medical center status by enhancing specialty construction and has received various hospital accreditation achievements in 2021 [63]. - The company is focusing on specialized capacity building in hospitals to enhance competitiveness in regional healthcare development [119]. - The company is committed to enhancing the capabilities of county-level medical services and improving the primary healthcare system [49]. - The company plans to add nearly 2,000 new hospital beds within two years, increasing total bed capacity to 10,000, significantly enhancing operational scale and profitability [119]. Financial Performance - The company's operating revenue for 2021 was ¥3,016,070,733.20, representing a 7.49% increase compared to ¥2,805,895,494.80 in 2020 [30]. - The net profit attributable to shareholders for 2021 was -¥371,431,516.93, a significant decline of 610.96% from -¥52,243,830.15 in 2020 [30]. - The net cash flow from operating activities was ¥277,294,763.28, a slight decrease of 2.29% from ¥283,796,318.85 in 2020 [30]. - The basic and diluted earnings per share for 2021 were -¥0.1991, reflecting a 611.07% decrease from -¥0.0280 in 2020 [30]. - Total assets at the end of 2021 were ¥6,690,205,812.98, an increase of 38.78% from ¥4,820,797,979.68 in 2020 [30]. - The company reported a quarterly operating revenue of ¥791,769,762.57 in Q4 2021, with a total annual revenue of ¥3,016,070,733.20 [36]. - The net profit attributable to shareholders in Q4 2021 was -¥312,357,886.43, contributing to the overall annual loss [36]. - The company experienced a significant increase in non-operating income, with government subsidies amounting to ¥10,098,941.29 in 2021 [40]. Governance and Compliance - The company has established a governance structure that complies with regulatory requirements, ensuring effective decision-making and accountability [129]. - The company has conducted three shareholder meetings during the reporting period, adhering to legal and regulatory standards [130]. - The company maintains complete independence from its controlling shareholders in terms of business operations, assets, personnel, and finance, ensuring no competitive relationship or dependency exists [135]. - The company has established a robust internal audit system with dedicated personnel to oversee internal controls, expenses, and asset management [135]. - The company has a comprehensive information disclosure management system to ensure timely and accurate communication with shareholders [135]. - The company has implemented a transparent investor relations management system to facilitate communication with stakeholders [135]. - The company has recognized the need for better management of fixed asset investments, particularly regarding construction projects that have been stalled since 2019 [195]. Restructuring and Future Plans - The company has entered a restructuring plan execution phase after the court approved the plan, but faces bankruptcy risks if the plan is not executed smoothly [7][9]. - The company is currently in the execution phase of its restructuring plan, having reduced the board of directors from 9 to 5 members, with plans to complete the restructuring before holding further board elections [197]. - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves for the fiscal year [10]. - The company will firmly promote the long-term strategy of health business in 2022, actively responding to the challenges of population aging and imbalanced medical supply [115]. - The company will increase investment in the technical and research capabilities of medical institutions, enhancing the R&D strength of traditional Chinese medicine and the scale advantages of medical institutions [115]. - The company plans to expand the production scale of "Duyiwei" and enhance annual sales revenue, considering integration through external mergers and acquisitions [118]. Human Resources and Management - The total number of employees at the end of the reporting period was 7,622, with 5,158 being technical staff [174]. - The company has a total of 212 retired employees who require financial support [174]. - The company has undergone significant management changes, with multiple resignations and appointments aimed at meeting development needs [146]. - The management team includes experienced professionals with backgrounds in finance, healthcare, and management [150][151]. - The company is addressing human resource risks by focusing on attracting and retaining high-quality medical and management talent [124]. Market and Product Development - The company has over 36 pharmaceutical products, including 8 exclusive products nationwide and 20 products listed in the medical insurance catalog [52]. - The company's main product, "Duyiwei Capsules," has been included in the National Essential Medicines List, which is expected to positively impact market prospects [124]. - The company is exploring new high-end domestic medical services and innovative biopharmaceutical research and market operations [55]. - The company is committed to developing new technologies and products to meet market demands [154]. - Future guidance indicates a focus on strategic acquisitions and partnerships to bolster growth [148]. Risks and Challenges - The company emphasizes the importance of risk awareness among investors regarding future operational plans and profitability forecasts [6]. - The company faces potential risks from policy changes in healthcare reform, which could impact operations [122]. - The company has acknowledged issues with accounts receivable, particularly with a significant amount overdue for more than one year, reflecting insufficient collection efforts [194].

Financial Performance - The company's operating revenue for Q1 2022 was ¥698,315,770.31, representing an increase of 8.98% compared to the same period last year[6] - The net profit attributable to shareholders was -¥47,235,805.90, a decline of 102.53% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥29,791,344.38, a decrease of 103.76% compared to the previous year[6] - The net profit for the quarter was ¥2,413,594.74, a significant recovery from a net loss of ¥48,758,930.91 in the same period last year[31] - The net profit attributable to the parent company was CNY 1,193,558.53, a decrease from a net loss of CNY 47,235,805.90 in the previous period[34] - The total comprehensive income attributable to the parent company was CNY 1,193,558.53, compared to a total comprehensive loss of CNY 47,235,805.90 in the prior period[34] - The basic and diluted earnings per share were both CNY 0.0006, a decline from CNY -0.0253 in the previous period[34] Cash Flow and Liquidity - The net cash flow from operating activities was ¥18,991,307.39, an increase of 68.76% year-on-year[6] - The cash inflow from operating activities totaled CNY 734,705,408.71, an increase from CNY 686,002,024.19 year-over-year[39] - The net cash flow from operating activities was CNY 32,049,044.25, up from CNY 18,991,307.39 in the prior year[39] - The net cash flow from investing activities was CNY -87,667,688.29, compared to CNY -60,508,581.39 in the previous period[41] - The net cash flow from financing activities was CNY 19,900,905.55, an increase from CNY 3,803,312.23 year-over-year[41] - The ending cash and cash equivalents balance was CNY 1,955,382,853.56, down from CNY 105,662,590.55 in the previous period[41] - The company reported a net increase in cash and cash equivalents of CNY -35,717,738.49, compared to a decrease of CNY -37,713,962.02 in the prior year[41] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,690,205,812.98, reflecting a growth of 1.29% from the end of the previous year[6] - The company's total assets increased to ¥6,776,359,687.06, compared to ¥6,690,205,812.98 in the previous period, marking a growth of 1.3%[28] - Total liabilities rose to ¥5,187,895,987.32, up from ¥5,104,155,707.98, indicating an increase of 1.6%[28] - The company's current assets total 3,029,966,838.82 RMB, slightly increasing from 3,023,848,238.36 RMB at the beginning of the year[22] - The cash and cash equivalents amount to 1,998,186,964.55 RMB, down from 2,033,160,168.10 RMB at the beginning of the year[22] - Accounts receivable increased to 616,533,876.71 RMB from 557,668,826.95 RMB[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 24,976[13] - The largest shareholder, Que Wenbin, holds 25.61% of the shares, totaling 477,639,999 shares[13] - The top ten shareholders include state-owned and private entities, with significant stakes held by Sichuan Industrial Revitalization Development Investment Fund and Northeast Securities[13] - The company reported a total of 475,687,230 shares under pledge, indicating potential liquidity concerns[13] Operational Changes and Risks - The company has entered the execution phase of its restructuring plan after the court's approval on April 22, 2022[21] - The company faces a risk of bankruptcy if the restructuring plan is not successfully executed[21] - The stock is under "delisting risk warning" and continues to be traded under the name "*ST Hengkang"[21] Expenses - Financial expenses increased by 66.51% to ¥36,557,171.98, primarily due to higher interest from acquisition funds and subsidiary borrowings[9] - The company recorded a decrease in non-operating income by 73.09%, amounting to ¥1,363,790.60 in the previous year[9] - The cash paid for the purchase of fixed assets increased by 44.84% to ¥87,827,688.29, indicating a rise in capital expenditures[12] - The company reported a decrease in sales expenses to ¥43,985,875.41 from ¥54,509,945.31, a reduction of 19.4%[31] - Research and development expenses were not specified, but the company continues to invest in innovation[31] Interest Income - The company reported a significant increase in interest income, which rose by 808.53% to ¥1,510,591.01 due to increased interest from restructured investments[9]

恒康医疗集团股份有限公司 2021 年第三季度报告 证券代码：002219 证券简称：*ST 恒康 公告编号：2021-101 恒康医疗集团股份有限公司 2021 年第三季度报告 本公司管理人、本公司及董事会全体成员保证公告内容真实、准确和完整， 没有虚假记载、误导性陈述或者重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------------------|------------------- ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,479,996,718.59, representing a 17.79% increase compared to CNY 1,256,467,897.88 in the same period last year[26]. - The net profit attributable to shareholders of the listed company was a loss of CNY 49,109,956.06, which is a 2.79% increase in loss compared to a loss of CNY 47,776,912.52 in the previous year[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of CNY 27,855,153.20, showing a 47.21% improvement compared to a loss of CNY 52,765,252.67 in the same period last year[26]. - The net cash flow from operating activities was CNY 124,592,501.89, a decrease of 4.83% from CNY 130,916,111.00 in the previous year[26]. - The total assets at the end of the reporting period were CNY 4,894,329,740.83, reflecting a 1.53% increase from CNY 4,820,797,979.68 at the end of the previous year[26]. - The net assets attributable to shareholders of the listed company decreased by 36.69% to CNY 84,736,204.88 from CNY 133,846,160.94 at the end of the previous year[26]. - The basic and diluted earnings per share were both CNY -0.0263, a decrease of 2.73% compared to CNY -0.0256 in the same period last year[26]. - The weighted average return on net assets was -44.93%, a decline of 16.98% from -27.95% in the previous year[26]. Operational Developments - The company is currently undergoing a restructuring process, which carries the risk of potential bankruptcy if the restructuring fails[7]. - The company has established a professional hospital management team to enhance operational efficiency and service quality across its hospitals[41]. - The company has a strong market presence with a stable and professional sales team, focusing on academic promotion to enhance product brand influence[41]. - The company is committed to the dual-driven strategy of medical services and pharmaceutical manufacturing, with a focus on building regional medical centers[36]. - The company has been in the pharmaceutical industry for over 20 years, with its "Duyiwei" brand recognized as a famous trademark in China[36]. - The company has developed 36 types of pharmaceuticals, including 7 exclusive products nationwide and 12 products listed in the Chinese Pharmacopoeia (2020 edition)[36]. Financial Position and Liabilities - The company's debt-to-asset ratio stands at 97.72%, indicating a high level of debt risk[71]. - The company faces litigation with a total amount of approximately 1.3 billion yuan due to various disputes, contributing to its high debt levels[71]. - The company has entered a restructuring process, which carries the risk of potential bankruptcy if the restructuring fails[71]. - The company has not distributed cash dividends or bonus shares for the half-year period[78]. - The company has no stock incentive plans or employee stock ownership plans in place during the reporting period[79]. - The company is actively monitoring healthcare reform policies to mitigate potential operational impacts from policy changes[71]. Revenue Breakdown - Medical service revenue reached ¥1,255,075,775.96, representing 84.80% of total revenue, with a year-on-year increase of 15.01%[45]. - The total revenue from the pharmaceutical segment was ¥218,328,400.17, accounting for 14.75% of total revenue, with a year-on-year growth of 36.93%[45]. Investments and Subsidiaries - The company has invested ¥59,200,000 in the JF Huayue (Taizhou) Asset Management Center, holding a 10% share as a limited partner[62]. - The company also committed ¥63,800,000 to the JF Huacai (Taizhou) Asset Management Center, maintaining a 10% stake as a limited partner[65]. - The company reported a net profit of ¥30,967,515.16 from its subsidiary Kangxian Duyiwei Biopharmaceutical Co., Ltd., contributing over 10% to the overall net profit[59]. - The total assets of Kangxian Duyiwei Biopharmaceutical Co., Ltd. amounted to ¥790,555,231.87, with a revenue of ¥167,245,079.46[59]. - The total assets of the subsidiary Siyang People's Hospital Co., Ltd. were reported at ¥564,336,129.41, generating revenue of ¥308,918,338.27[59]. Shareholder Information - As of June 30, 2021, the controlling shareholder, Mr. Que Wenbin, had 638,509,999 shares frozen, accounting for 34.23% of the total share capital[113]. - The largest shareholder, Que Wenbin, holds 34.23% of the shares, totaling 638,509,999 shares, with a decrease of 154,000,000 shares during the reporting period[157]. - The second-largest shareholder, Sichuan Industrial Revitalization Development Investment Fund Co., Ltd., holds 6.03% of the shares, totaling 112,500,000 shares[157]. - The total number of shares pledged, marked, or frozen is 636,557,230 shares, primarily by Que Wenbin[157]. Legal and Compliance Issues - The company is involved in a significant lawsuit regarding a performance commitment dispute, with the plaintiff claiming a compensation of 91.03 million CNY for unmet performance targets in 2017[101]. - The company has been ordered to pay 22.96 million CNY in a ruling related to a share transfer dispute, which includes 12 million CNY in attorney fees and penalties[101]. - A court ruling has mandated the company to pay 92.77 million CNY related to a share transfer payment dispute[101]. - The company is currently appealing a court decision requiring it to pay approximately 387.92 million CNY in partnership equity acquisition payments and overdue interest[104]. - The company faces a claim of 43.66 million CNY in another partnership equity acquisition dispute, which is also under appeal[104]. - The company is involved in a loan contract dispute where it is required to repay 60 million CNY in principal and interest[107]. - The company has been ordered to pay 48 million CNY in a loan contract dispute, where it is held liable as a guarantor[107]. - The company is facing an arbitration claim for approximately 2.5 million EUR in intermediary service fees[111]. Environmental and Social Responsibility - The company has not faced any environmental penalties during the reporting period and adheres to relevant environmental laws[83]. - The company is committed to environmental protection, with all environmental facilities operating normally and meeting regulatory standards[85].